Sign for Notice Everyday    Sign Up| Sign In| Link| English|

Our Sponsors

    Receive Latest News

    Feedburner
    Share Us


    How to properly investigate OOS/OOT Results

    View: 225

    Website http://bit.ly/2ru2Sae | Want to Edit it Edit Freely

    Category cyber crime investigation;gmp compliance audit checklist

    Deadline: July 28, 2017 | Date: July 28, 2017

    Venue/Country: New York, U.S.A

    Updated: 2017-06-26 18:26:10 (GMT+9)

    Call For Papers - CFP

    Overview

    The speaker will provide sound training on how to recognize and investigate atypical or out of specification results, using approaches which have been recommended by regulatory authorities, performing appropriate investigations.

    This webinar will review the regulatory requirements for investigating an OOS Investigation.

    The responsibilities of the analyst, the supervisor and QA will be discussed. A detailed flow chart will be used to help the attendees clearly understand the steps and the order in which they are to be performed. The structure of an Investigation report which properly documents the investigation will be discussed.

    Why Should You Attend

    The lack of or Inadequate procedures for handling out of specification (OOS) situations and failure investigations are amongst the most frequently found deviations in FDA warning letters.

    Most companies have procedures but either they are not adequate or are not followed. This seminar will guide attendees through the entire process from detection an out-of-specification result to informal and formal laboratory and batch investigations

    Areas Covered in this Webinar

    FDA requirements for handling OOS/ OOT results

    Phase I- Laboratory Phase of Investigations

    Phase II a Full Scale Investigation

    Concluding an Investigation

    Out-of Trend investigations

    Common pitfalls during OOS Investigations

    Review of recent OOS related citations in Warning Letters

    Learning Objectives

    Learn the responsibilities of Analysts and Supervisors

    Listen to what the FDA looks for in terms of Human Errors

    Describe when a Full Investigation should be triggered

    Describe the frequency for Re-testing and Re-sampling

    Learn how to implement the corrective and preventive action plans (CAPA)

    Who Will Benefit

    Quality Assurance/Quality Control Directors, Managers, and Specialists

    Regulatory Affairs/Regulatory Compliance Directors, Managers, and Specialists

    Quality Control Laboratory Staff

    For more detail please click on this below link:

    http://bit.ly/2ru2Sae

    Email: referralsatcomplianceglobal.us

    Toll Free: +1-844-746-4244

    Tel: +1-516-900-5515

    Fax: +1-516-900-5510


    Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
    Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.